Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated February 6, 2025. The document serves as a regulatory disclosure of transactions in Novo Nordisk shares conducted by the company's board members, executives, and associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The transactions reported occurred primarily on February 5, 2025, with one transaction on February 6, 2025.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively details insider trading activity. The following transaction metrics are reported:
- Transaction Types: "Other transaction" (transfers under Long Term Incentive programmes) and "Sale of shares."
- Share Prices: Sales occurred at prices ranging from DKK 614.55 to DKK 621.01. Incentive transfers were recorded at DKK 0.00.
- Trading Venues: Transactions took place on Nasdaq Copenhagen, CBOE Europe, Turquoise Europe, and outside trading venues.
Material Changes and Transaction Details
The filing reports specific share movements for the following individuals:
- Lars Fruergaard Jørgensen (President and CEO):
- Received 98,702 shares via Long Term Incentive programme (DKK 0.00).
- Sold a total of 33,423 shares across multiple venues (Aquis, CBOE, Turquoise, Nasdaq) for an aggregate value of approximately DKK 20,969,127.
- Ludovic Helfgott (Executive Vice President):
- Received 27,765 shares via Long Term Incentive programme (DKK 0.00).
- Sold 20,990 shares on Nasdaq Copenhagen for an aggregate value of approximately DKK 12,928,840.
- Camilla Sylvest (Executive Vice President):
- Received 30,728 shares via Long Term Incentive programme (DKK 0.00).
- Sold 15,364 shares on Nasdaq Copenhagen for DKK 9,448,860.
- Maziar Mike Doustdar (Executive Vice President):
- Received 36,956 shares via Long Term Incentive programme (DKK 0.00).
- Sold 1,852 shares on Nasdaq Copenhagen for DKK 1,138,154.
- Other Executives (Karsten Munk Knudsen, Martin Holst Lange, Tania Sabroe, Marcus Schindler, Henrik Ehlers Wulff):
- Reported only "Other transactions" (incentive transfers) ranging from 10,561 to 32,448 shares at DKK 0.00. No sales were reported for these individuals in this filing.
- Liselotte Sofie Hyveled (Board Member):
- Received 1,407 shares via Long Term Incentive programme (DKK 0.00). No sales reported.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, outlook, management commentary on business performance, or specific risk factors. It is a compliance disclosure regarding insider trading. The company's general purpose is stated as driving change to defeat serious chronic diseases, with a heritage in diabetes, employing approximately 72,000 people in 80 countries.
Key Facts for Investor Verification
- Verify the net change in share ownership for the CEO and other executives by comparing these sales against their total holdings.
- Confirm that the sales by executives (Jørgensen, Helfgott, Sylvest, Doustdar) were executed in accordance with pre-established trading plans (Rule 10b5-1 or equivalent), as is standard for such volume.
- Note the share price range of DKK 614.55 - 621.01 as a market reference point for February 5-6, 2025.
- Observe that a significant portion of the reported activity involves the vesting of Long Term Incentive shares (transfers at DKK 0.00) rather than open market purchases.